EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Impact of trametinib on the neuropsychological profile of NF1 patients

Eve Lalancette, Édith Cantin, Marie-Ève Routhier, Chantal Mailloux, Marie-Claude Bertrand, Dorsa Sadat Kiaei, Valérie Larouche, Uri Tabori, Cynthia Hawkins, Benjamin Ellezam, Jean-Claude Décarie, Yves Théoret und 17 weitere

Journal of Neuro-Oncology · 2024

DOI: 10.1007/s11060-024-04624-3 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Eve Lalancette und 28 weiteren Autor:innen. Beteiligte Einrichtung: CHU Sainte-Justine Research Center, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada. eve.lalancette.1@umontreal.ca. Hauptthemen laut MEDLINE: Pyridones, Pyrimidinones, Neurofibromatosis 1, Neuropsychological Tests. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Fonds de Recherche du Québec - Santé, Canadian Institutes of Health Research, Fondation du Grand défi Pierre Lavoie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The use of trametinib in the treatment of pediatric low-grade gliomas (PLGG) and plexiform neurofibroma (PN) is being investigated in an ongoing multicenter phase II trial (NCT03363217). Preliminary data shows potential benefits with significant response in the majority of PLGG and PN and an overall good tolerance. Moreover, possible benefits of MEK inhibitor therapy on cognitive functioning in neurofibromatosis type 1 (NF1) were recently shown which supports the need for further evaluation. METHODS: Thirty-six patients with NF1 (age range 3-19 years) enrolled in the phase II study of trametinib underwent a neurocognitive assessment at inclusion and at completion of the 72-week treatment. Age-appropriate Wechsler Intelligence Scales and the Trail Making Test (for children over 8 years old) were administered at each assessment. Paired t-tests and Reliable Change Index (RCI) analyses were performed to investigate change in neurocognitive outcomes. Regression analyses were used to investigate the contribution of age and baseline score in the prediction of change. RESULTS: Stable performance on neurocognitive tests was revealed at a group-level using paired t-tests. Clinically significant improvements were however found on specific indexes of the Wechsler intelligence scales and Trail Making Test, using RCI analyses. No significant impact of age on cognitive change was evidenced. However, lower initial cognitive performance was associated with increased odds of presenting clinically significant improvements on neurocognitive outcomes. CONCLUSION: These preliminary results show a potential positive effect of trametinib on cognition in patients with NF1. We observed significant improvements in processing speed, visuo-motor and verbal abilities. This study demonstrates the importance of including neuropsychological evaluations into clinical trial when using MEK inhibitors for patients with NF1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesPyrimidinonesNeurofibromatosis 1Neuropsychological TestsHumansMaleFemaleAdolescentChildYoung AdultChild, PreschoolGliomaBrain NeoplasmsAdultProtein Kinase InhibitorsAntineoplastic Agents

Stichwörter der Autor:innen

MEK inhibitorNeurofibromatosis type 1Neuropsychological profileTrametinib

Substanzen

PyridonesPyrimidinonesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • CHU Sainte-Justine Research Center, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada. eve.lalancette.1@umontreal.ca.
  • Division of Neuropsychology, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, QC, Canada.
  • Division of Neuropsychology, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada.
  • CHU Sainte-Justine Research Center, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada.
  • Division of Hemato-Oncology, Department of Pediatrics, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec City, QC, Canada.
  • Division of Hemato-Oncology, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada.

Förderung

  • Fonds de Recherche du Québec - Santé
  • Canadian Institutes of Health Research
  • Fondation du Grand défi Pierre Lavoie
  • Association de la Neurofibromatose du Québec

Zitieren

APA

Lalancette, E., Cantin, É., Routhier, M. È., Mailloux, C., Bertrand, M. C., Kiaei, D. S., Larouche, V., Tabori, U., Hawkins, C., Ellezam, B., Décarie, J. C., Théoret, Y., Métras, M. É., McKeown, T., Ospina, L. H., Vairy, S., Ramaswamy, V., Coltin, H., Sultan, S., …, & Lippé, S. (2024). Impact of trametinib on the neuropsychological profile of NF1 patients. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04624-3

Vancouver

Lalancette E, Cantin É, Routhier MÈ, Mailloux C, Bertrand MC, Kiaei DS, et al. Impact of trametinib on the neuropsychological profile of NF1 patients. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04624-3

BibTeX
@article{Lalancette2024,
  author = {Lalancette, Eve and Cantin, Édith and Routhier, Marie-Ève and Mailloux, Chantal and Bertrand, Marie-Claude and Kiaei, Dorsa Sadat and Larouche, Valérie and Tabori, Uri and Hawkins, Cynthia and Ellezam, Benjamin and Décarie, Jean-Claude and Théoret, Yves and Métras, Marie-Élaine and McKeown, Tara and Ospina, Luis H and Vairy, Stéphanie and Ramaswamy, Vijay and Coltin, Hallie and Sultan, Serge and Legault, Geneviève and Bouffet, Éric and Lafay-Cousin, Lucie and Hukin, Juliette and Erker, Craig and Caru, Maxime and Dehaes, Mathieu and Jabado, Nada and Perreault, Sébastien and Lippé, Sarah},
  title = {Impact of trametinib on the neuropsychological profile of NF1 patients},
  journal = {Journal of Neuro-Oncology},
  year = {2024},
  doi = {10.1007/s11060-024-04624-3}
}
Kostenlos starten →